Kilitch Drugs Reports Strong Q4 Growth Amid Rising Interest Expenses and Liquidity Concerns

Kilitch Drugs (India), a microcap player in the Pharmaceuticals & Drugs industry, has recently reported its financial results for the quarter ending December 2024. The evaluation changes reflect a notable shift in the company's score, which has risen significantly over the past three months.
The financial data indicates a robust performance in several key areas. Profit Before Tax less Other Income (PBT) reached Rs 6.52 crore, marking a substantial growth compared to the average of the previous four quarters. Similarly, net sales for the quarter stood at Rs 56.17 crore, also showing a significant increase over prior averages. Profit After Tax (PAT) and Operating Profit (PBDIT) both achieved their highest levels in the last five quarters, suggesting a strong operational performance.

However, not all aspects are favorable. The interest expense has surged dramatically, indicating a rise in borrowings, while cash and cash equivalents have reached their lowest point in the last six half-yearly periods, raising concerns about short-term liquidity. Additionally, the Debtors Turnover Ratio has declined, suggesting a slower pace in settling receivables.

Overall, Kilitch Drugs has experienced a revision in its score, reflecting the mixed trends in its financial health.

Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.